Progenics Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
March 20 2018 - 8:30AM
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company
developing innovative medicines and imaging analysis technology for
targeting and treating cancer, announced today that Mark R. Baker,
Chief Executive Officer, will present at the 17th Annual Needham
Healthcare Conference in New York City on Tuesday, March 27, 2018
at 3:00 p.m. Eastern Daylight Time.
A live webcast of the presentation will be
available in the Media Center of the Progenics
website, www.progenics.com. To ensure a timely connection,
users should register at least 15 minutes prior to the scheduled
start. An archive of the event will be available for 90 days.
About Progenics
Progenics develops innovative medicines and
other technologies to target and treat cancer. Progenics' pipeline
includes: 1) therapeutic agents designed to precisely target cancer
(AZEDRA®, 1095, and PSMA TTC), 2) PSMA-targeted imaging agents for
prostate cancer (1404 and PyL™), and 3) imaging analysis
technology. Progenics' first commercial product, RELISTOR®
(methylnaltrexone bromide) for opioid-induced constipation, is
partnered with Valeant Pharmaceuticals International, Inc.
This press release may contain projections and
other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics'
estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics'
current perspective of existing trends and information as of the
date of this communication. Forward looking statements generally
will be accompanied by words such as "anticipate," "believe,"
"plan," "could," "should," "estimate," "expect," "forecast,"
"outlook," "guidance," "intend," "may," "might," "will,"
"possible," "potential," "predict," "project," or other similar
words, phrases or expressions. Such statements are predictions
only, and are subject to risks and uncertainties that could cause
actual events or results to differ materially. These risks and
uncertainties include, among others, the cost, timing and
unpredictability of results of clinical trials and other
development activities and collaborations, such as the Phase 3
clinical program for 1404; our ability to successfully develop and
commercialize the products of EXINI Diagnostics AB; the
unpredictability of the duration and results of regulatory review
of New Drug Applications (NDA) and Investigational NDAs, including
our NDA for AZEDRA and related
inspections of Progenics’ and its contract
manufacturing organizations’ facilities and other sites and
other requirements that will need to be met before any approval is
obtained; market acceptance for approved products; the
effectiveness of the efforts of our partners to market and sell
products on which we collaborate and the royalty revenue generated
thereby; generic and other competition; the possible impairment of,
inability to obtain and costs of obtaining intellectual property
rights; possible product safety or efficacy concerns, general
business, financial, regulatory and accounting matters, litigation
and other risks. More information concerning Progenics and such
risks and uncertainties is available on its website, and in its
press releases and reports it files with the U.S. Securities and
Exchange Commission, including those risk factors included in
its Annual Report on Form 10-K for the annual period
ended December 31, 2017. Progenics is providing the
information in this press release as of its date and, except as
expressly required by law, Progenics disclaims any intent or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this release. For more
information, please visit www.progenics.com. Information on or
accessed through our website or social media sites is not included
in the company's SEC filings.
(PGNX-F)
Contact: |
Melissa Downs |
|
Investor Relations |
|
(646) 975-2533 |
|
mdowns@progenics.com |
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024